Prima BioMed enters agreement with Fraunhofer Institute for Cell Therapy and Immunology to produce cancer vaccine

01-Jun-2010 - Germany

Prima BioMed enters an agreement with Fraunhofer Institute for Cell Therapy and immunology to produce a cancer vaccine. The agreement represents a crucial step in the development and production of CVac™ in Europe. Establishment of a subsidiary in Leipzig is envisioned.

The preparation for production of CVac™ for the European trial has already commenced, and Prima BioMed Ltd and the Fraunhofer IZI are working together to prepare the facility to support CVac™ clinical trials in Europe in early 2011. This represents a significant milestone on the pathway to commercialisation of CVac™ in the European market.

Prima Chief Operating Officer and Managing Director for Europe, Matthew Lehman said: “The Fraunhofer Institute is among the foremost research and development organisations in the world and Prima is delighted to enter into this collaborative arrangement (…)”.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances